A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

被引：5

作者：

Vaishampayan, Ulka N.

Narayan, Vivek

Wise, David

Lang, Joshua Michael

Lowentritt, Benjamin H.

Mellado, Begona

Carles, Joan

Saez, M. Isabel

Abida, Wassim

Taplin, Mary-Ellen

Azad, Arun

Wang, Karrie

Barbash, Olena

Ferron-Brady, Geraldine

Fecteau, Doug

Khaled, Ahmed Hussein

Dhar, Arindam

De Bono, Johann S.

机构：

[1] Karmanos Canc Ctr, Detroit, MI USA

[2] Penn Med Abramson Canc Ctr, Philadelphia, PA USA

[3] New York Univ Med Ctr, New York, NY USA

[4] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA

[5] Chesapeake Urol Associates, Towson, MD USA

[6] Hosp Clin Barcelona, Barcelona, Spain

[7] Vall Hebron Univ Hosp Inst Oncol, Barcelona, Spain

[8] H Univ Virgen Victoria Reg Malaga, Inst Biomed Res Malaga CNIO IBIMA Genitourinary C, CRIS Canc Fdn Prostate Canc Res Grp, Malaga, Spain

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Monash Univ, Clayton, Vic, Australia

[12] GlaxoSmithKline, Collegeville, PA USA

[13] Inst Canc Res & Royal Marsden Hosp, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.TPS391

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS391

引用

页数：1

共 50 条

[21] A phase I/IIa, open-label, dose-escalation and expansion study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ107 in Chinese patients with advanced solid tumors
Li, Jin
Guo, Ye
Peng, Wei
Xue, Junli
Zhao, Wei
Ge, Xiaoxiao
Xue, Liqiong
Tang, Wenbo
Zhou, Li
Zhang, Min
Guo, Bingshi
Wang, Liping
Guo, Jiyuan
Cui, Feifei
Suo, Haiyun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[22] An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
Janku, Filip
Hamilton, Erika Paige
Chu, Christina
Richardson, Debra L.
Arend, Rebecca Christian
Kuida, Keisuke
Achour, Haroun
Ruiz-Soto, Rodrigo
Hays, John L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
Johnson, Geoffrey
Lengyelova, Eva
Nordquist, Luke T.
Prasad, Vikas
Anderson, Monique
Gervasio, Othon
Parker, Michelle
Miller, Robert M.
Sartor, A. Oliver
Tagawa, Scott T.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS246 - TPS246
[24] A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I. Shapiro
Patricia LoRusso
Daniel C. Cho
Luna Musib
Yibing Yan
Matthew Wongchenko
Ilsung Chang
Premal Patel
Iris T. Chan
Sandra Sanabria-Bohorquez
Raymond D. Meng
Johanna C. Bendell
Investigational New Drugs, 2021, 39 : 163 - 174
[25] A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Shapiro, Geoffrey, I
LoRusso, Patricia
Cho, Daniel C.
Musib, Luna
Yan, Yibing
Wongchenko, Matthew
Chang, Ilsung
Patel, Premal
Chan, Iris T.
Sanabria-Bohorquez, Sandra
Meng, Raymond D.
Bendell, Johanna C.
INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 163 - 174
[26] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Alejo Rodriguez-Vida
Pablo Maroto
Albert Font
Cristina Martin
Begoña Mellado
Alex Corbera
Mayra Orrillo
Oscar Reig
Rosa Querol
Alejandro Rios-Hoyo
Laia Cano
Judith Alonso
Gemma Martinez
Susana Galtes
Alvaro Taus
Maria Martinez-Garcia
Nuria Juanpere
Oscar Juan
Joaquim Bellmunt
British Journal of Cancer, 2023, 128 : 21 - 29
[27] Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Fizazi, Karim
Massard, Christophe
Bono, Petri
Jones, Robert
Kataja, Vesa
James, Nicholas
Garcia, Jorge A.
Protheroe, Andrew
Tammela, Teuvo L.
Elliott, Tony
Mattila, Leena
Aspegren, John
Vuorela, Annamari
Langmuir, Peter
Mustonen, Mika
LANCET ONCOLOGY, 2014, 15 (09): : 975 - 985
[28] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Rodriguez-Vida, Alejo
Maroto, Pablo
Font, Albert
Martin, Cristina
Mellado, Begona
Corbera, Alex
Orrillo, Mayra
Reig, Oscar
Querol, Rosa
Rios-Hoyo, Alejandro
Cano, Laia
Alonso, Judith
Martinez, Gemma
Galtes, Susana
Taus, Alvaro
Martinez-Garcia, Maria
Juanpere, Nuria
Juan, Oscar
Bellmunt, Joaquim
BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 21 - 29
[29] First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer.
Beeram, Muralidhar
Wang, Judy Sing-Zan
Mina, Lida A.
Patnaik, Amita
Pambid, Mary Rose
Jayanthan, Aarthi
Huynh, My-my
Dunn, Sandra Elaine
Los, Gerrit
Dorr, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.
Buelow, Ben
Dalvi, Pranjali
Dang, Kevin
Patel, Ashwin
Johal, Kiran
Pham, Duy
Panchal, Shailee
Liu, Yvonne
Fong, Lawrence
Sartor, A. Oliver
McKean, Meredith
Schellenberger, Ute
Iyer, Suhasini
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →